Description
“ Graft vs. Host Disease- Competitive Landscape, Technology and Pipeline Analysis, 2016”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Graft Versus Host Disease. Graft-versus-host disease( GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation( HSCT) that occurs when the donated( graft) cells are rejected and attack the host ' s cells as foreign.
Request a sample of this report @ http:// www. orbisresearch. com / contacts / request-sample / 209352.
The complexity of immune-mediated disease occurs due to the interaction between the adaptive immunity of donor and recipient. It can progress from mild to severe forms as either acute GVHD( aGVHD) or chronic GVHD( cGVHD). Both aGVHD and cGVHD commonly affect organs such as the skin, gastrointestinal( GI) tract, liver, oral mucosa, and eyes. It is the worldwide cause of mortality and morbidity. Several factors are responsible for Graft versus Host Disease such as blood transfusion, bone marrow transplant, stem cell transplant.
Leading Companies Profiles Analyzed in Report:
• Bellicum Pharmaceuticals
• Kymab Limited
• Targazyme
• Multistem
• ImmuneTarget Inc.
• Athersys
• AstraZeneca plc.
• Fate Therapeutics, Inc.
• Therakos Inc.
• Mallinckrodt Pharmaceuticals
• Athersys
• AstraZeneca plc.
Purchase a copy of this report @ http:// www. orbisresearch. com / contact / purchase / 209352
Report Highlights:
• The new report, provides a Graft Versus Host Disease Landscape across the globe
• The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages www. orbisresearch. com; + 1( 214) 884-6817; + 9120-64101019